Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

PTC Initiates Phase 2 Clinical Trial of Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy in Pediatric Patients Between the Ages of Two and Five Years

PTC Therapeutics has announced that they have initiated a Phase 2 clinical trial of Translarna™ (ataluren) for children 2 to 5 years old. Details of site locations, etc. are on clinicaltrials.gov.  Below is the announcement from PTC. We are pleased to inform you that PTC Therapeutics has initiated a Phase 2 clinical trial of Translarna™ (ataluren), […]


Jesse’s Journey announces research funding commitment of more than $1M

On June 21, 2016 Jesse’s Journey held a special media announcement at the Best Western Plus Lamplighter Inn & Conference Centre, to release details of our 2016 research funding. Three new research projects have been approved by the Board of Directors for new and existing research projects in 2016 totalling more than $1 million.  The new […]


Marathon Pharmaceuticals submits deflazacort NDA to treat Duchenne muscular dystrophy

Marathon Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for its deflazacort investigational drug to treat Duchenne muscular dystrophy (DMD). Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. It has fast track status, orphan drug designation and rare pediatric disease designation for DMD. Click […]


Students help Defeat Duchenne

Thank you to the students and staff of Jack Chambers public school, Eagle Heights public school and Saunders Secondary school for participating in Defeat Duchenne Month 2016! At Jack Chambers, students bought a chance to estimate how many candies were in a jar – and raised $815! Students at Eagle Heights invited John Davidson to […]


Translarna not recommended in Scotland

Translarna, the first ever treatment to address the underlying causes of Duchenne muscular dystrophy, has received a negative funding recommendation from the Scottish Medicines Consortium (SMC) on the basis of cost. This is despite the proactivity and efforts of Action Duchenne, families, and other charities to inform SMCs evaluation and ensure that the patient voice remained at […]


Defazacort Improves Lung Function in Advanced Duchenne MD Patients, Marathon Reports

Duchenne muscular dystrophy (DMD) patients at more advanced disease stages, those reliant on wheelchairs, showed improved lung function when treated with deflazacort compared to prednisone, Marathon Pharmaceuticals reported in a presentation at the recent MDA Clinical Conference in Arlington, Virginia. The presentation, “Effect of deflazacort and prednisone versus placebo on pulmonary function in boys with Duchenne Muscular Dystrophy who have lost ambulation,” added to […]


Jesse's Journey logo with photo of Jesse and John waving Canadian flag.

20th Anniversary

2015 is a very special year for Jesse’s Journey – it marks 20 years since John Davidson pushed his son Jesse in his wheelchair across Ontario to raise funds and awareness for Duchenne muscular dystrophy. It was on this historic trek that Jesse’s Journey was born. Because of the generosity and support from all of […]


Wendy Sanderson-Culley

Welcome Wendy

Welcome our new Managing Director We would like to extend a warm welcome to Wendy Sanderson-Culley as the new Managing Director of Jesse’s Journey.  Rick Moss will continue in a new transitional role at the Journey office until December 2016 and will be working on special projects with the staff team. Wendy brings more than […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.